Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RUNX2
REST API REST API
Homo sapiens
RUNX2 is differentially expressed in 306 experiments: 157 organism parts: skeletal muscle, bone marrow, ... (155 more);, 200 disease states: normal, control, ... (198 more);, 111 cell types 402 cell lines 39 compound treatments and 78 other conditions.
Synonyms CCD, AML3, PEBP2A1, PEBP2aA1, CBFA1, CCD1
Orthologs ENSCING00000002253 (Ciona intestinalis)   RUNX2 (Bos taurus)   RUNX2 (Gallus gallus)   runx2a (Danio rerio)   Runx2 (Mus musculus)   runx2b (Danio rerio)   Runx2 (Rattus norvegicus)   RunxB (Drosophila melanogaster)   RunxA (Drosophila melanogaster)   run (Drosophila melanogaster)   lz (Drosophila melanogaster)   Runx2 (Mus musculus)   runx2 (Xenopus laevis)   RUNX2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, ATP binding, nucleus, positive regulation of transcription, DNA-dependent, osteoblast differentiation, ossification, sequence-specific DNA binding transcription factor activity
InterPro Term AML1_Runt, AML1/Runt_N, RunxI, TF_Runt-rel_RUNX
UniProt Accession Q13950, Q5T802, Q5T801, Q32MY8, F6RGB9, F8W8U5
Gene-Disease Assocation CLEIDOCRANIAL DYSPLASIA; CCD
Search EB-eye ENSG00000124813
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
SW480
3
E-MTAB-37, E-MEXP-1014, E-GEOD-18005
A549
2
E-GEOD-6013, E-GEOD-3202
DU145
2
E-GEOD-17482, E-GEOD-20089
MCF-7
2
E-GEOD-20081, E-GEOD-5823
primary culture
2
E-GEOD-2450, E-GEOD-1657
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
396 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-21750, ... (51 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18265, E-GEOD-20033, E-GEOD-18147
cardiac myocyte
2
E-AFMX-5, E-TABM-145
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD21lo transitional B cell
1
E-GEOD-17186
eNK cell
1
E-GEOD-20499
dendritic cell-derived osteoclast
1
E-MEXP-2019
105 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, ... (65 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-MTAB-37, E-GEOD-4290, E-MTAB-62, E-GEOD-4412
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
acute lymphoblastic leukemia, chemotherapy response
1
E-MTAB-62
poliovirus-infected
1
E-MEXP-1072
194 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-GEOD-697, ... (26 experiments)

Factor Value U/D Experiments
none
5
8
E-GEOD-5741, E-GEOD-5824, E-GEOD-20719, E-MEXP-1958, E-GEOD-412, ... (13 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
hydrogen peroxide
1
E-GEOD-5339
ponasterone A
1
E-GEOD-3113
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
valproic acid
1
E-GEOD-1615
33 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374, E-GEOD-20499, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-GEOD-20115, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20540, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-GEOD-20559, E-TABM-276

Individual
studied in E-TABM-325, E-TABM-740, E-MEXP-2069, E-GEOD-1926, E-GEOD-20876, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.525 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM